You are here

Validating the MicroKine Assay for Use in Identifying Personalized Precision Therapies for Pediatric Sepsis

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41HD090759-01
Agency Tracking Number: R41HD090759
Amount: $224,944.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NICHD
Solicitation Number: PAR13-091
Solicitation Year: 2013
Award Year: 2018
Award Start Date (Proposal Award Date): 2018-01-01
Award End Date (Contract End Date): 2018-09-30
Small Business Information
Dexter, MI 48130
United States
DUNS: 080356705
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (734) 764-5302
Business Contact
Phone: (734) 436-1050
Research Institution
ANN ARBOR, MI 48109-5001
United States

 Nonprofit College or University

Project Summary Abstract
PreDxion BioLLC is a precision medicine diagnostic company developing an assay platformthe
MicroKineassay cartridge and readerthat measures serum proteins in less thanminutes from
a single drop of bloodThis fastactionable information allows for the first time individualized
precision medicine aimed at reducing pediatric morbidity and mortality in pediatric sepsisthe number
one killer of children worldwideThe goal of this STTR is to move the current research grade
MicroKineplatform to a validatedscalablecommercial grade alpha platformPhase Ithen to a
fully automated beta platformPhase IIwhile demonstrating the feasibility of using the platform in
the clinical workflowUsing serum sample from pediatric patients with sepsis PreDxion will validate
the MicroKineplatform demonstrating the feasibility of rapid risk stratification and identification of
therapeutic targets by addressing the following aimsSpecific Aim Idetermine the feasibility of the
alpha version of the MicroKineassay to rapidly risk stratify pediatric patients with severe sepsis and
Specific Aim IIdemonstrate feasibility of rapidly determining the serum cytokines values in high risk
septic pediatric patientsSuccessful commercialization of the MicroKineplatform will provide the
basis for expanding the current sepsis guidelines to individualized precision guidelines in high risk
individuals reducing the high rates of mortality in these individuals Project Narrative
PreDxion Bio is developing a rapid serum protein assayMicroKinethat will provide clinicians
information to guide precise individual therapies to children at highest risk from dying from sepsisthe
number one killer of children worldwideThe assay would change the current way children with
sepsis are treated by providing serum inflammatory protein levels in less thanminutes allowing
clinicians to act quicklyThe MicroKineassay provides this information from a drop of blooda
necessity when caring for children

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government